2minutemedicine.com23h
Ticagrelor monotherapy reduces bleeding risk compared to dual antiplatelet therapy for patients following coronary stenting
Ticagrelor was non-inferior to DAPT for the incidence of major adverse cardiovascular and cerebrovascular events. 2.
2minutemedicine.com1d
Adaptimmune’s Afami-cel is the first FDA-approved T-cell receptor therapy for synovial sarcoma
Afami-cel (Tecelra) is the first genetically engineered T-cell receptor therapy for synovial sarcoma Afami-cel demonstrated ...
2minutemedicine.com1d
Semaglutide reduces heart failure events in patients with preserved ejection fraction
Patients in the semaglutide group reported fewer heart failure events than those in the placebo group. 2. No significant ...
2minutemedicine.com3d
Ponsegromab for the Treatment of Cancer Cachexia
1. Ponsegromab at increasing doses resulted in a mean increase in body weight compared to placebo; 1.22 kg (2.21%) in the 100-mg group, 1.92 kg (2.99%) in the 200-mg group, and 2.81 kg (5.46) in the ...
2minutemedicine.com3d
Datopotamab deruxtecan may be a novel improvement for inoperable breast cancer
1. Compared to chemotherapy, patients with inoperable hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer receiving the antibody-drug conjugate (ADC) ...